A 20-cent 'wonder drug' is being studied as a colon-cancer-fighting supplement, and it looks promising
Scientists who presented at the American Association for Cancer Research conference in Chicago last week are studying how metformin — the most popular diabetes medication worldwide — interacts with tough-to-treat colon cancer cells. Their research is still early and ongoing.
"Metformin seems like it could have a really interesting supplemental approach to therapy," Holli Loomans-Kropp, a gastrointestinal cancer prevention researcher at The Ohio State University, who is leading the ongoing study, told Business Insider. "We're opening up some doors to what this could do."
Previous research found that people taking metformin for diabetes have lower colon cancer rates, suggesting the drug may be doing something protective to help prevent cancer from developing. This new study is one of the first to look at whether metformin could actually fight colon cancer cells once the disease develops.
Based on what Loomans-Kropp and her team have seen so far in cell-culture dishes, metformin could become a helpful "supplement" to certain cancer treatment regimens in the future. It wouldn't be potent enough to treat cancer on its own, but could be used alongside other treatments.
Loomans-Kropp is especially excited about the drug's potential in treating a common type of colon cancer caused by a mutated KRAS gene, which tends to be very tough to treat. Her research is still in the early stages; further animal testing is required before human clinical trials can begin.
A drug that changes how the body uses energy
One of the big benefits Loomans-Kropp sees to studying metformin for colon cancer treatment is a practical one — it's a drug that's already widely accessible and affordable.
"I always like to ask the question: Are there medications or agents that we already know, that are already used, that we have safety/toxicity profiles for, that we can then repurpose for something else?"
Metformin has been studied and used by millions of patients worldwide. And as an off-patent, generic drug, it's cheap — it costs 10 to 20 cents per pill.
It's sometimes referred to as a " wonder drug" by doctors for its beneficial effects outside blood-sugar control. Scientists have studied it for heart health, cancer prevention, and dementia.
Metformin works for diabetes because it changes the way the body processes and produces sugar. Some scientists believe it may hold promise as an antiaging drug. Like exercise or fasting, metformin regulates how the body uses energy and encourages autophagy, a process that allows the body to process old and damaged cells. Loomans-Kropp hopes that metformin could also inhibit colon cancer cells from using energy to grow and develop.
"If metformin maybe can be used to redirect or change how the cell uses energy, which then ultimately changes how it divides and how it proliferates, this could be a mechanism to exploit," Loomans-Kropp said.
The same energy-shifting mechanism has longevity researchers excited about metformin as a tool for disease prevention.
Dr. Nir Barzilai, a leading longevity researcher who suspects metformin may be beneficial for healthy aging, said metformin may be a "suitable" option for cancer prevention. When it comes to fighting cancer, he agrees with Loomans-Kropp that more study is needed.
"Let the science lead," he told Business Insider in an email.
Loomans-Kropp is hoping that if these initial cancer cell results are successful, she can begin testing metformin as colon cancer treatment on animals within a year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vox
12 hours ago
- Vox
Rudolph and all of the other reindeer are probably dying from climate change
is an environmental correspondent at Vox, covering biodiversity loss and climate change. Before joining Vox, he was a senior energy reporter at Business Insider. Benji previously worked as a wildlife researcher. It's bad enough that climate change is ruining the dream of a white Christmas for many people, as warming makes snow in some regions less likely. Now, apparently, it's coming for reindeer, too. Reindeer aren't just creatures of Christmas myth; they're real animals — a kind of deer that live in the Arctic, from northern Europe and Russia to North America, where they're commonly known as caribou. These animals are remarkably adapted to cold weather, sporting thick fur, a snout that warms the air they take in, and uniquely structured hooves that help them shovel snow to find food, such as lichen. But they've also survived bouts of Arctic warming that occurred thousands of years ago, thanks to their ability to travel long distances in search of colder habitats. These adaptations are, however, no match for modern climate change. The Arctic is warming quickly from a higher baseline temperature compared to natural fluctuations in the distant past. Wild reindeer search for food under the midnight sun on the Svalbard archipelago in the Arctic Circle. Ben Birchall/PA Wire Over the last few decades, wild Arctic reindeer populations have declined by about two-thirds, from 5.5 million to around 1.9 million, largely due to warming, according to previous research. Rising temperatures can affect reindeer health directly — causing the animals to overheat and get sick — and indirectly by limiting their supply of food. Now, it's clear those declines will likely continue. A new study in the journal Science Advances found that if the world doesn't quickly rein in greenhouse gas emissions, the global wild reindeer population could plummet by nearly 60 percent by the end of the century. Those declines will be far more severe in North America, where they could exceed 80 percent, according to the study's models, which reconstructed 21,000 years of reindeer population data using fossil records, DNA, and other data sources. That's because North America is expected to lose more habitat that can support reindeer to warming than elsewhere, said Damien Fordham, a study author and researcher at the University of Adelaide. Even under a more modest emissions scenario — in which countries cut back what they spew into the atmosphere — the study projects steep population declines. You can see these results in the chart below, which shows projected declines based on a high and moderate emissions scenario, respectively. 'These results are absolutely concerning,' said Jennifer Watts — Arctic program director at the Woodwell Climate Research Center, a nonprofit research organization — who was not involved in the new study. 'Given how quickly and severely the Arctic is warming at present, the results from this study are not overly surprising, and should serve as yet another wake-up call for humans to curtail anthropogenic drivers of climate warming.' The study offers yet another example of how climate change is threatening biodiversity and how those threats in turn affect humans. Reindeer are not only a critical food source for some Arctic Indigenous communities — like Alaskan Natives and the Inuit people of North America — but also a cornerstone of their culture, similar to salmon or wolves for some tribal nations in other parts of the US. If major polluting nations, like the US, China, and India don't curtail their emissions, it could further endanger the food sovereignty of those communities. Beyond their direct impact on human well-being, reindeer also shape the tundra ecosystems — quite literally making them what they are — by limiting the growth of trees and shrubs, spreading seeds, and fertilizing the soil. 'We should care about the fate of reindeer and caribou with the same concern we give to the fate of polar bears and other Arctic animals,' Watts told Vox. 'The well-being of entire ecosystems and humans living across the Arctic depend on their survival.'
Forbes
17 hours ago
- Forbes
An Unexpected Clue To How Metformin, The World's Top Diabetes Drug, Works
Metformin is an unassuming hero of modern medicine. For more than sixty years, this humble pill has been a mainstay of diabetes care, helping millions of people manage their blood sugar. It lowers blood sugar, improves cholesterol, modestly reduces weight, and is so safe it's prescribed to millions worldwide. And yet, for decades, scientists haven't fully understood how it works. The standard explanation has long been that metformin works in the liver, reducing how much sugar it sends into the bloodstream. It also helps muscles and fat cells respond more effectively to insulin. More recent research added other suspects: the gut, which can tweak hormones and the microbiome, and a cellular pathway called mTOR, a major regulator of metabolism and longevity. But a new study published in Science Advances suggests that part of metformin's magic might be happening somewhere unexpected: in the brain. The Blood Sugar Command Center Researchers turned their attention to a protein called Rap1, found in a small pocket of the brain known as the ventromedial hypothalamus (VMH). This area is a metabolic mission control, coordinating hunger, energy use, and glucose balance. When scientists switched off Rap1 in this brain region in mice, blood sugar levels fell, even without metformin. But when they kept Rap1 switched on, metformin lost its blood-sugar-lowering power. The results hint that, at the doses typically prescribed, metformin may partly work by silencing Rap1's activity in the brain, not just by acting on the liver or gut. Most of us think of blood sugar control as the domain of the pancreas, liver, and muscles. Yet the brain is deeply involved. The VMH works like an air traffic controller, taking in information from across the body and sending out signals to adjust glucose production and use. Metformin, it seems, may be tapping into this high-level control system. By dialing down Rap1 activity, the drug might trigger a cascade of neural instructions that ripple out to the rest of the body, improving how tissues handle sugar. Beyond Diabetes Metformin has drawn attention far beyond the diabetes world. It's being studied for its potential to slow certain aspects of aging, with researchers probing whether its effects on pathways like mTOR could help extend not just lifespan but healthspan. The discovery of the brain-Rap1 link opens new possibilities. Could this same circuit be part of metformin's longevity effects? If so, drugs that target Rap1 or its related pathways might someday offer more precise ways to improve metabolism or promote healthy aging, perhaps without some of metformin's side effects. When Old Drugs Tell New Tales This does not mean discarding what is already known about metformin's effects on the liver, muscles, and gut. Those mechanisms are still in play. But at everyday doses, the brain may have a starring role in how the drug works. At much higher doses, peripheral mechanisms can take over, but in real-world clinical use, the brain's contribution could be key. The finding is also a reminder that the brain and body are not separate actors in the story of metabolism. They are in constant conversation, adjusting and responding to keep systems in balance. And as this research shows, an old drug can reveal something entirely new about that conversation. Even after six decades, metformin still has secrets to share: secrets that may change how both the medicine itself and the intricate links between the brain, the body, and health are understood.
UPI
a day ago
- UPI
Clinical trial shows promise for new pancreatic cancer vaccine
A small clinical trial suggests a new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back. File Photo by Debbie Hill/UPI | License Photo A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small clinical trial suggests. Pancreatic cancer is one of the most lethal cancers, with a five-year survival rate of about 13%, according to the American Cancer Society. Further, up to 80% of cases return after treatment, the National Institutes of Health says. "If you were to ask me what disease most needs something to prevent recurrences, I'd say this one," Dr. Zev Wainberg, a leader of the trial, told NBC News. He's co-director of the University of California, Los Angeles gastrointestinal oncology program. The experimental vaccine targets KRAS gene mutations, which are found in about 25% of all cancers, the University of Texas MD Anderson Cancer Center says. This includes up to 90% of pancreatic cancers and roughly 40% of colon cancers. While these mutations have long been considered impossible to treat with drugs, researchers are finding new ways to target them. The vaccine, called ELI-002 2P, uses small chains of amino acids called peptides to train the immune system to spot and destroy cells with KRAS mutations. Unlike many cancer vaccines that are custom-made for each patient, this one is designed to be off the shelf, meaning it doesn't require the tumor to be sequenced before it's used, NBC News reported. The Phase 1 study -- reported Tuesday in Nature Medicine -- included 20 people with pancreatic cancer and five with colon cancer. All had KRAS mutations and had already undergone surgery and chemotherapy. Blood tests after surgery showed microscopic evidence of residual disease - cancer cells too small to see on scans. These leftover cells can cause the cancer to spread and return. Post-surgery, participants received up to six priming doses of the vaccine, with 13 also getting booster shots. In all, the process took six months. Here's what the results showed: 85% (21 of 25 participants) had an immune response to the KRAS mutations. About two-thirds of those had a strong enough response to help clear lingering cancer cells. Nearly 70% developed immunity to other tumor targets not included in the vaccine. A few "super-responders" had exceptionally strong immune reactions and the best outcomes. In the pancreatic cancer group, patients survived for an average of 29 months, staying recurrence-free for more than 15 months after vaccination. "That far exceeds the rates with resectable [surgically removable] cancers," Wainberg said. Cancer vaccines have been difficult to create because cancer cells share many proteins with healthy cells, making safe targets hard to find. Advances in mRNA technology and faster gene sequencing are now making more effective cancer vaccines possible. The peptides in this vaccine also have a unique "tail" that helps them stay in lymph nodes, where immune cells are activated -- a feature past peptide vaccines didn't have, said Stephanie Dougan, an associate professor at Dana-Farber Cancer Institute in Boston, who was not involved in the study. More research is needed to confirm the findings, and a Phase 2 trial is now underway to compare the vaccine with standard care. "The fact that the long-term survival really correlated with T-cell response suggests that the vaccine caused this," Dougan said, referring to the specific immune cells activated by the vaccine. "The idea that you can target KRAS is really exciting." More information The Mayo Clinic has more on pancreatic cancer. Copyright © 2025 HealthDay. All rights reserved.
